Navigation Links
Salivary diagnostics, the 'magic mirror' to your health ... at your personal computer
Date:4/5/2008

Accuracy, convenience, and non-invasiveness are the most critical characteristics for any diagnostic tool. A new concept, Salivaomics Knowledge Base (SKB), an in silico (i.e., performed on computer or via computer simulation) saliva diagnostic atlas, is launching today during the 37th Annual Meeting of the American Association for Dental Research in Dallas, Texas.

With people increasingly adopting a digital life, the SKB will serve as a catalyst for future development and expansion of salivary diagnostics. For over three years, saliva has shown genuine promise as a diagnostic tool for oral cancer detection. As a result, the scientific community and general public have developed a keen interest in its value.

Central to the SKB is the recent creation of two diagnostic alphabets in saliva, the proteome and the transcriptome. In the SKB, the salivary proteome and transcriptome are mapped to 23 human chromosomes, totaling1166 distinct proteins and 851 unique mRNA transcripts in saliva. The available information presently includes profiles from healthy males and females, as well as oral cancer patients. These profiles can be used to determine distinct differences between groups of interest. For example, if one wants to know the differences in the salivary protein or transcriptome profiles of males and females, the user-friendly interface can be utilized to retrieve information from the database. First, an overview of the biomarker distribution on the 23 human chromosomes can be determined. Then, one can zoom in on specific gene segments to extract more detailed information, all done on ones personal computer.

This is the first step of this SKB initiative. The database is expanding and will soon include information for pancreatic cancer, breast cancer, lung cancer, ovarian cancer, diabetes,and Alzheimers disease. The short-term goal of the SKB is to share information with scientists globally in an effort to reduce redundancy and enhance t
'/>"/>

Contact: Linda Hemphill
lhemphill@iadr.org
703-299-8091
International & American Association for Dental Research
Source:Eurekalert

1

GOOD

Page: 1 2

Related medicine news :

1. Sentillion Positioned in Visionaries Quadrant in Leading Industry Analyst Firms User Provisioning Magic Quadrant
2. Saks Fifth Avenue Unveils Five Magical Holiday Gifts
3. The Magic Johnson Foundation and Abbott Expand Focus of Campaign to End Black AIDS to African-American Women in 2008
4. Cookie Johnson and Abbott Bring I Stand With Magic: Campaign to End Black AIDS to Los Angeles to Educate African-American Women on HIV/AIDS
5. Parents Face Tough Questions When Santas Magic Fades
6. Microban International Partners with Magic American Products to Launch Magic(R) Brand Products with Microban(R) Antimicrobial Product Protection
7. Spouses often mirror each others health habits
8. PARADE Magazine Features Smart Genetics and Alzheimers Mirror
9. Penn study finds pro-death proteins required to regulate healthy immune function
10. UCLA researchers identify markers that may predict diabetes in still-healthy people
11. Air pollution linked to cardiovascular risk indices in healthy young adults
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:The Paper Tiger Document Management and Filing System Software Announces "Windows 7 Compatibility" 2Health News:The Paper Tiger Document Management and Filing System Software Announces "Windows 7 Compatibility" 3Health News:The Paper Tiger Document Management and Filing System Software Announces "Windows 7 Compatibility" 4Health News:The Paper Tiger Document Management and Filing System Software Announces "Windows 7 Compatibility" 5Health News:You Never Get a Second Chance to Make a First Impression: High-Definition for the Web 2Health News:Dr. 90210 Rhinoplasty Specialist Now Accommodates Both the East and West Coast 2Health News:World-Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non-Invasive Treatment of Veins 2Health News:World-Renowned Vascular Surgeon to Conduct Training at Harvard Medical School Site on Non-Invasive Treatment of Veins 3Health News:Perkins: Senate Would Rather Mandate Abortion Funding Than Enact 'Health Care Reform' 2
Other Medicine News:Health News:Choice Hotels Selects PAI as Qualified Vendor to Offer Health Benefits to Part-Time, Hourly Workers in Its Franchisee Base 2Health News:Choice Hotels Selects PAI as Qualified Vendor to Offer Health Benefits to Part-Time, Hourly Workers in Its Franchisee Base 3Health News:Boston Scientific Completes Enrollment in Landmark Heart Failure Trial 2Health News:Boston Scientific Completes Enrollment in Landmark Heart Failure Trial 3Health News:'Size Does Matter ... and So Does Shape ... When It Comes to Teeth,' Says Cosmetic Dentist, Dr. Denise Fundora 2Health News:The Leapfrog Group Releases 2008 Hospital Survey Offering Consumers Greater Assurance of Safety 2Health News:The Leapfrog Group Releases 2008 Hospital Survey Offering Consumers Greater Assurance of Safety 3Health News:The Leapfrog Group Releases 2008 Hospital Survey Offering Consumers Greater Assurance of Safety 4Health News:Stored Ovarian Tissue Needs Testing Before Re-Implantation 2Health News:Life Brokerage Partners Strengthens Premium Finance Programs 2
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 2Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 3Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 4Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 5Novartis Tasigna(R) (nilotinib) Trial Shows Superior Results to Glivec(R) (imatinib) in Newly Diagnosed, Chronic Phase Chronic Myeloid Leukaemia 6Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4Binge Drinking Not Just a Rite of the Young 62247 1Binge Drinking Not Just a Rite of the Young 62247 2Healing from the Inside Out 3A Compelling New Book Explores the Intricate Connection between Body Soul and Better Health 62245 1Healing from the Inside Out 3A Compelling New Book Explores the Intricate Connection between Body Soul and Better Health 62245 2Baxa to Sponsor ASHP Midday Symposium 3A Creating a Culture of Safety in Pharmacy A Panel Discussion on Lessons Learned 62243 1Baxa to Sponsor ASHP Midday Symposium 3A Creating a Culture of Safety in Pharmacy A Panel Discussion on Lessons Learned 62243 2Baxa to Sponsor ASHP Midday Symposium 3A Creating a Culture of Safety in Pharmacy A Panel Discussion on Lessons Learned 62243 3
Other Medicine Technology:Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 2Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 3Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 4Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 5Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 6Pivotal Phase III Data Confirm the Efficacy and Safety of Arpida's Intravenous Iclaprim in Treating Patients With Complicated Skin and Skin Structure Infections 7Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 2Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 3Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 4Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 5Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 6Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 7Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults 8